SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL
Stefan Schreiber 1
Geert R. D'Haens 2
Fraser Cummings 3
Peter Irving 4
Byong Duk Ye 5
Yoorim An 6
Dong-Hyeon Kim 6
Sangwook Yoon 6
Shomron Ben-Horin 7
Walter Reinisch 8
1 University Hospital Schleswig-Holstein, Kiel, Germany
2 Amsterdam University Medical Centers, Amsterdam, Netherlands
3 University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
4 Guy’s and St Thomas’ Hospital, London, United Kingdom
5 University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of
6 Celltrion Healthcare, Incheon, Korea, Republic of
7 Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel
8 Medical University of Vienna, Vienna, Austria
Session
IBD (Posters)
Conference
UEG Week Virtual 2021
Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]